Breaking News

Actavis to Acquire Warner Chilcott

May 20, 2013

Will create leading specialty pharma company

Actavis, Inc. has entered into a definitive agreement to acquire Warner Chilcott in a transaction valued at approximately $8.5 billion. Once completed, the transaction will create a leading global specialty pharma company with approximately $11 billion in combined annual revenues, and the third-largest U.S. specialty pharma company with approximately $3 billion in annual revenues focused on women's health, gastroenterology, urology and dermatology. 
 
At the close of the transaction, expected by year-end 2013, Actavis and Warner Chilcott will be combined under a new company incorporated in Ireland called Actavis plc, and will be led by the current Actavis leadership team. 
 
"We have set as our strategic corporate objective to build a leading global specialty pharmaceutical company," said Paul Bisaro, president and chief executive officer of Actavis. "The combination of Actavis and Warner Chilcott creates a strong specialty brand portfolio focused in therapeutic categories with strong growth potential, and is supported by a deep pipeline of development programs. The combination is commercially and financially compelling, and reshapes the specialty pharmaceutical universe by creating a powerful global competitor.”
 
"The Warner Chilcott team has built a powerful specialty brands business with a strong pipeline, and this compelling transaction brings together two complementary organizations with the potential to create even more value for shareholders," said Roger Boissonneault, president and chief executive officer of Warner Chilcott. "Paul Bisaro and his team have been executing on their vision to build a global and diverse company at the forefront of the specialty pharmaceutical industry, and the addition of Warner Chilcott should enhance the ability of the combined company to successfully execute that vision, and accelerate Actavis' evolution."

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important